{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:01:37Z","timestamp":1782831697036,"version":"3.54.5"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Lasers Surg Med"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec><jats:title>Background and Objective<\/jats:title><jats:p>Oxymetazoline, an \u03b1\u20101A agonist, is approved by the United States Food and Drug Administration (FDA) for treatment of persistent facial erythema associated with rosacea and induces vasoconstriction by interacting with \u03b1 receptors. The objective of our study was to study the microvascular effects of oxymetazoline and pulsed dye laser (PDL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>A dorsal window chamber was surgically installed on 20 mice. Each animal was assigned to one of four experimental groups: saline alone, oxymetazoline alone (10\u2009\u03bcl applied once daily\u2009\u00d7\u20097 days), saline\u2009+\u2009PDL (saline applied 5 minutes before PDL irradiation [10\u2009mm spot, 1.5\u2009ms pulse duration, 7\u2009J\/cm<jats:sup>2<\/jats:sup> delivered to epidermis]), or oxymetazoline\u2009+\u2009PDL (10\u2009\u03bcl oxymetazoline applied 5 minutes before PDL and then once daily\u2009\u00d7\u20097 days). Brightfield and laser speckle imaging were performed for 7 days to monitor vascular architectural and functional changes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We observed persistent blood flow in all of the saline\u2010only and oxymetazoline\u2010only experiments. A higher rate of vascular shutdown was observed with oxymetazoline\u2009+\u2009PDL (66.7%) compared with saline\u2009+\u2009PDL alone (16.7%). Oxymetazoline application increased venule diameter at 5 minutes post\u2010application and decreased both arteriole and venule diameters at 60 minutes post\u2010application.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The combination protocol of oxymetazoline\u2009+\u2009PDL induces persistent vascular shutdown observed 7 days after irradiation. This result may be associated with the acute vascular effects of oxymetazoline. Oxymetazoline\u2009+\u2009PDL should be evaluated as a treatment for cutaneous vascular disease, including rosacea and port wine birthmarks. Lasers Surg. Med. \u00a9 2019 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/lsm.23186","type":"journal-article","created":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T05:21:05Z","timestamp":1574486465000},"page":"17-22","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Microvascular Effects of Pulsed Dye Laser in Combination With Oxymetazoline"],"prefix":"10.1002","volume":"52","author":[{"given":"Alexis","family":"Kelly","sequence":"first","affiliation":[{"name":"Beckman Laser Institute and Medical Clinic University of California 1002 Health Sciences Rd Irvine California 92617"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pai","sequence":"additional","affiliation":[{"name":"Beckman Laser Institute and Medical Clinic University of California 1002 Health Sciences Rd Irvine California 92617"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Lertsakdadet","sequence":"additional","affiliation":[{"name":"Beckman Laser Institute and Medical Clinic University of California 1002 Health Sciences Rd Irvine California 92617"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Choi","sequence":"additional","affiliation":[{"name":"Beckman Laser Institute and Medical Clinic University of California 1002 Health Sciences Rd Irvine California 92617"},{"name":"Department of Biomedical Engineering, Henry Samueli School of Engineering University of California 3120 Natural Sciences II Irvine California 92697\u20102715"},{"name":"Edwards Life Sciences Center for Advanced Cardiovascular Technology University of California 2400 Engineering Hall Irvine California 92697\u20102730"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5988-2197","authenticated-orcid":false,"given":"Kristen M.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Beckman Laser Institute and Medical Clinic University of California 1002 Health Sciences Rd Irvine California 92617"},{"name":"Department of Dermatology University of California 118 Medical Surge Irvine California 92697\u20102400"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"issue":"2","key":"e_1_2_8_2_1","first-page":"47","article-title":"Quality of life in individuals with erythematotelangiectatic and papulopustular rosacea","volume":"11","author":"Zeichner JA","year":"2018","journal-title":"J Clin Aesthet Dermatol"},{"issue":"7","key":"e_1_2_8_3_1","first-page":"28","article-title":"Topical a\u2010agonist therapy for persistent facial erythema of rosacea and the addition of oxmetazoline to the treatment","volume":"10","author":"Del Rosso JQ","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1370370"},{"issue":"1","key":"e_1_2_8_5_1","first-page":"1201","article-title":"Topical oxymetazoline cream 1.0% for persistent facial erythema associated with rosacea: Pooled analysis of the two phase 3, 29\u2010day, randomized, controlled REVEAL trials","volume":"17","author":"Stein\u2010Gold L","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_6_1","first-page":"S39","article-title":"Optical coherence tomography evaluation of topical oxymetazoline hydrochloride treatment efficacy for rosacea","volume":"50","author":"Ryan H","year":"2018","journal-title":"Lasers Surg Med"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001507"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.22189"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2011.07.004"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.22000"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1117\/1.3285504"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1006\/phrs.2001.0857"},{"issue":"2","key":"e_1_2_8_13_1","first-page":"H710","article-title":"Different alpha\u2010adrenoceptor subtypes mediate constriction of arterioles and venules","volume":"270","author":"Leech CJ","year":"1996","journal-title":"Am J Physiol"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2009.00805.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10439-011-0436-9"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.20890"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.304"}],"container-title":["Lasers in Surgery and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flsm.23186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lsm.23186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/lsm.23186","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lsm.23186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T13:01:57Z","timestamp":1694091717000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/lsm.23186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1002\/lsm.23186"],"URL":"https:\/\/doi.org\/10.1002\/lsm.23186","archive":["Portico"],"relation":{},"ISSN":["0196-8092","1096-9101"],"issn-type":[{"value":"0196-8092","type":"print"},{"value":"1096-9101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,22]]},"assertion":[{"value":"2019-10-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}